A Phase II Study of Dasatinib Combined with Induction Chemotherapy in Previously Untreated de novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia to Assess Safety and Tolerability

DOI number 10.58109/sg1n-dk60
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Andrew Grigg (Austin Hospital)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 20 patients
  • Patients with Philadelphia positive ALL
  • Introduced testing of desatinib (TKI)
  • Includes Diagnostic information about patients (demographic and diagnostic details, Treatment, clinical outcome, serial info on BCR/ABL testing
  • Full patient cohort achieved
  • Complete and clean dataset
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Chemotherapy
ANZCTR Reference ACTRN12607000609459
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
ALL06